focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 324.00
Bid: 322.00
Ask: 325.00
Change: -13.00 (-3.86%)
Spread: 3.00 (0.932%)
Open: 321.00
High: 326.00
Low: 311.00
Prev. Close: 337.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

HUTCHMED to Host Company Update

17 May 2021 07:00

RNS Number : 8027Y
Hutchmed (China) Limited
17 May 2021
 

Press Release

 

Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors

 

 - HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to provide updates on recent progress and upcoming milestones -

 

Hong Kong, Shanghai & Florham Park, NJ - Monday, May 17, 2021: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM) today announces that it will host a virtual investor update event on Wednesday, May 26, 2021. Members of the senior management team will provide updates on product launches in China, preparations for US commercialization, R&D, as well as a review of new data presented at the 2021 ASCO Annual Meeting.

 

Analysts and investors are invited to join a conference call and audio webcast presentation. The event will take place at 8:00 a.m. Eastern Daylight Time / 1:00 p.m. British Summer Time (BST) / 8:00 p.m. Hong Kong Time (HKT) on Wednesday, May 26. A first Q&A session will immediately follow the prepared remarks. For Asian investors, a recording of the webcast will be available for viewing the following morning and a second Q&A session will start at 12:00 noon HKT on Thursday, May 27.

 

The event will be webcast live and can be accessed at www.hutch-med.com/event. Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM: HCM) (formerly Hutchison China MediTech) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,200 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the U.S. Securities and Exchange Commission and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

 

 

CONTACTS

 

Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

 

Americas - Brad Miles,Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw,FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)HUTCHMED@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi,Brunswick

+852 9850 5033 (Mobile) / +852 9783 6894 (Mobile)HUTCHMED@brunswickgroup.com

Nominated Advisor

Freddy Crossley / Atholl Tweedie,Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAARMATMTBBMJB
Date   Source Headline
21st Jun 20194:35 pmRNSPrice Monitoring Extension
19th Jun 20194:35 pmRNSPrice Monitoring Extension
14th Jun 20199:00 amRNSSurufatinib Phase III Study Meets Primary Endpoint
12th Jun 20199:18 amRNSBlock Admission Applications & Total Voting Rights
10th Jun 201912:07 pmRNSSecond Price Monitoring Extn
10th Jun 201912:02 pmRNSPrice Monitoring Extension
6th Jun 20197:00 amRNSDisclosure Update
31st May 20194:40 pmRNSSecond Price Monitoring Extn
31st May 20194:35 pmRNSPrice Monitoring Extension
29th May 201912:06 pmRNSResults of Extraordinary General Meeting
22nd May 201911:03 amRNSGrant of Share Options under Share Option Scheme
3rd May 20197:00 amRNSNotice of EGM & Shareholder Circular
24th Apr 20191:54 pmRNSResults of AGM
15th Apr 20197:30 amRNSDisclosure Update
15th Apr 20197:00 amRNSHK Listing Application - Proposed Global Offering
29th Mar 20197:00 amRNSStart of Phase IIb/III Surufatinib Trial in China
28th Mar 20197:30 amRNSSavolitinib Lung Cancer Presentations at AACR
25th Mar 20197:00 amRNSVesting of awards under Long Term Incentive Plan
21st Mar 20197:00 amRNSChi-Med 2018 Annual Report and Notice of AGM
11th Mar 201912:54 pmRNSPublication of Form 20-F
11th Mar 20197:00 amRNS2018 FY Results and Key Clinical Programs Update
12th Feb 20197:00 amRNSSavolitinib PRCC Data to be presented at ASCO GU
8th Feb 20197:00 amRNSChi-Med to Announce 2018 Final Results
7th Jan 20197:00 amRNSChi-Med Presents at JPM Healthcare Conference
31st Dec 20187:00 amRNSBlocklisting Six Monthly Return
31st Dec 20187:00 amRNSTotal Voting Rights
24th Dec 201812:41 pmRNSSecond Price Monitoring Extn
24th Dec 201812:36 pmRNSPrice Monitoring Extension
20th Dec 20187:13 amRNSChi-Med announce Savolitinib program update
20th Dec 20187:00 amRNSAmendment to Lilly Agreement on Fruquintinib
14th Dec 20187:21 amRNSTR-1: Form for notification of major holdings
30th Nov 20187:00 amRNSTotal Voting Rights
29th Nov 20188:00 amRNSChi-Med Enters into Multiple Collaborations
26th Nov 20187:00 amRNSFirst Commercial Launch of Fruquintinib Capsules
16th Nov 20187:00 amRNSPhase III FALUCA Trial Results for Fruquintinib
31st Oct 20187:00 amRNSTotal Voting Rights
22nd Oct 201810:05 amRNSGrant of Share Options under Share Option Scheme
18th Oct 20187:00 amRNSChi-Med Initiates a Ph I Trial of HMPL-523 for AML
5th Oct 20187:00 amRNSAppointment of HSBC Bank plc as Broker in London
5th Sep 20187:00 amRNSFruquintinib Approved for CRC in China
31st Aug 20187:00 amRNSTotal Voting Rights
7th Aug 201810:00 amRNSGrant of Share Options under Share Option Scheme
27th Jul 20187:00 amRNS2018 Interim Results and Clinical Programs Update
23rd Jul 20187:00 amRNSStart of Sulfatinib US Phase Ib/II PoC trial
29th Jun 20187:02 amRNSTotal Voting Rights
29th Jun 20187:01 amRNSBlocklisting Six Monthly Return
29th Jun 20187:00 amRNSChi-Med to Announce Half-Year Financial Results
7th Jun 201810:00 amRNSGrant of Share Options under Share Option Scheme
4th Jun 20189:41 amRNSFurther Fruquintinib FRESCO Trial Data - ASCO 2018
31st May 20187:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.